Finally, Axsome's late-stage pipeline could result in additional regulatory approvals over the next few years. That could seriously lift its revenue. News on these potential products and any eventual approvals also could send the shares higher. Of course, as with any biotech company, there's always a risk of a candidate stumbling during development. And that could hurt share performance.